65,437 trials
Hypertension · Hemorrhage
Primary: Median Time to Achieve Target SBP Range (≤160 mmHg to ≥140 mmHg) Within 30 Minutes of Initiation of Clevidipine — 5.5 minutes
Diabetes · Diabetes Mellitus, Type 2
Primary: Glycosylated Haemoglobin (HbA1c) — 7.34; 7.23 percentage of glycosylated haemoglobin — p=0.3406
Sickle Cell Disease
Primary: Acute Chest Syndrome — 11; 11; 22; 85 participants
Metabolic Diseases · Hyperlipidemias · Metabolic Disorder
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point — -2.0; -47.3 percentage of baseline — p=<0.001
Lipid Metabolism, Inborn Errors · Hypercholesterolemia, Autosomal Dominant · Hyperlipidemias
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -16.2; -2.6; -32.4; 30.6 percentage of baseline
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
Sudden Cardiac Arrest
Primary: Decision to Receive an ICD — 28; 14 Participants
Head and Neck Cancer
Primary: Number of Participants With Complete Response — 39 participants
Healthy · Dry Eye
Primary: Mean Retention Time — 87.4; 61.9 Days
Hepatitis C
Primary: Patients Who Are Negative for Hepatitis C Virus (HCV) RNA at 3 Months Post-transplant: Intent-to-Treat Analysis (ITT) — 0; 5; 6 participants — p=0.0477
Recurrent Prostate Carcinoma · Stage I Prostate Cancer · Stage IIA Prostate Cancer
Primary: Proportion of Patients Free of PSA Progression at 6 Months (Prior to the Start of Androgen Ablation) — 0.625 Proportion of patients
NSCLC · Solid Tumors
Primary: Phase 1 Safe and Tolerable Phase 2 Dose. — 10 mg/m^2
Adolescent Methamphetamine Abuse
Primary: Feasibility of Retaining Adolescents in Trial — 33.3; 49.3 days — p=0.08
Lumbar Spinal Stenosis
Primary: Changes in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.3 units on a scale
Glioblastoma
Primary: Overall Survival (OS) — 13.17; 17.58 months